LONDON – Curve Therapeutics Ltd. has gone straight from £4.5 million (US$6.1 million) in startup funding to signing a $1.7 billion drug discovery agreement with Merck & Co. Inc. The deal will see Curve apply its mammalian cell discovery technology to five oncology and neuroscience targets nominated by Merck.